EXTRACORPOREAL PHOTOPHERESIS MAGGIE FOSTER MANAGER ROTHERHAM PHOTOPHERESIS UNIT
|
|
- Adela Thomas
- 5 years ago
- Views:
Transcription
1 EXTRACORPOREAL PHOTOPHERESIS MAGGIE FOSTER MANAGER ROTHERHAM PHOTOPHERESIS UNIT
2 AIM OF PRESENTATION Explain about Photopheresis. Rotherham service. Conditions treated Advantages /disadvantages of XTS & CELLEX. guide lines for safe treatments. Treatment schedules. Response. Blood primes.
3 ALSO KNOWN AS:- PHOTOPHERESIS ECP EXTRA CORPOREAL CHEMOTHERAPY EXTRA CORPOREAL PHOTOIMMUNE THERAPY
4 WHAT IS IT? Photo= Light Extra corporeal = Out side the body Immune Therapy = works on white cells Therefore Photopheresis is a light activated treatment taking place outside the body
5 ROTHERHAM PHOTOPHERESIS UNIT Rotherham General Hospital has been delivering this specialised treatment since 1994 and in 2009 the Photopheresis Unit at Rotherham achieved Foundation Unit status. The service at Rotherham is expanding rapidly and in 2009 with Paediatric medical support began to treat patients under the age of sixteen
6 DR RICHARD EDELSON In the 1970 s Dr Edelson noted that by removing circulating cancer cells from patient with Sezary Syndrome by repetitive leukapheresis showed a temporary improvement in their skin s collaborated with Therakos to design a device to expose a fraction of patients white blood cells to ultra violet light and psoralen a(light sensitising drug)
7 HISTORY OF ECP Ammi-Majus(Bishop weed) Bishop weed (Ammi- Majus) was found to have medicinal properties and was used by the Ancient Egyptians.But has only been available in a chemically synthesized form since the 1970s
8 UVADEX (METHOXSALEN) Is a Psoralen a group of Chemical compounds found naturally in Bishop weed. Is inert until activated by UVA. Remains active for 24hours after exposure to UVA Host becomes sensitive to sunlight. Contains natural diuretic Also found in figs, parsnips,mustard, limes,carrots celery. Is absorbed by plastic.
9 REFERAL SYSTEM
10 CONDTIONS TREATED AT ROTHERHAM Cutaneous T-Cell Lymphoma (CTCL) Chronic Graft Versus Host Disease (GVHD) Atopic Eczema Scleroderma
11 GRAFT VERSUS HOST DISEASE Graft Versus Host Disease is a complication following an Allogeneic Transplant either Bone Marrow or Stem Cells. The donor s (Graft) cells attacks the Patients (Host) organs and tissues impairing their ability to function and increasing the patient s risk of infection. It can attack single or multiple areas.
12 On the surface of many human cells is an inherited set of genetic markers called human leukocyte antigens (HLA).Unless you are an identical twin no two peoples are the same In Photopheresis the cells we collect and treat are T-cells, a white cell that sees any thing foreign in the body and attacks it, they can also recognise self from non self human cells that belong in one persons body and those that don t. T-cells uses a persons HLA markers to distinguish self from non self In GVHD the donors transplanted cells identifies the HLA markers on the patients cells as non self launches an attack on the patients organs and tissues. Because the patients immune system is suppressed following transplant it cannot fight back.
13 CUTANEOUS T-CELL LYMPHOMA (CTCL) Cutaneous T-Cell Lymphoma belongs to the Non- Hodgkin group. It is a rare type of cancer caused by malignant T-cells migrating to the skin. Affects age group years of age. More common in men Most common types of CTCL are :- Mycosis Fungoides Sezary Syndrome.
14 SEZARY SYNDROME Advanced type of CTCL. Large areas of skin affected. Redness and scaling Skin my look thicker in parts Swollen Lymph Nodes Abnormal Lymphocytes in blood. ECP recommended at this stage.
15 MYCOSIS FUNGOIDES Most common type of CTCL. Develops and progresses slowly. Often misdiagnosed. Three Stages:- Patch stage-red or brown scaly flat patches Plaques-Red 0r brown itchy scaly raised areas. Tumours- Mushroom shaped tumours. No known cure.
16 PLAQUE STAGE TUMOUR STAGE
17 MACHINES THROUGH THE AGES present 2006-present
18 XTS ADVANTAGES Quieter Less stressful DISADVANTAGE Takes 20 minutes to prime Longer treatment times More chances of vasovagal episodes Single needle mode only. Not continuous flow system. Latex injection ports
19 CELLEX ADVANTAGES Shorter treatment times 1-21/2 hours Only 7 minutes to prime machine Latex free ports Continuous flow system ( double needle mode) Discontinuous Flow System Single needle mode) Patients with Low body weights or low Haemoglobins can be treated. Less risks of Vasovagal episodes. DISADVANTAGES Very sensitive to touch or tremors Numerous alarms More nurses input
20 PRE ECP Haemoglobin to be above 10 Haematocrit to be 28% 0r above Platelets to be above 20 Weight 40kg Apyrexial Patient to drink 2-3 litres of fluid 2 days prior treatment Avoid alcohol and caffeine Low fat diet prior to treatment With hold anti hypertensive or diuretics on day of treatment ( till after treatment completed)
21
22 POST ECP Wear high factor sun cream 15 or above Wear UVA sunglasses for 48hours after treatment Do not carry heavy bags on arm used for treatment Keep pressure bandage in situ for 4-6 hours (do not sleep with bandage on)
23 SIDE EFFECTS Mild fever for a few hours post ECP Increase in urine output Feels tired Bleeding from cannula site Bruising around cannula site Metallic taste Sparkly bits in eyes Haematuria
24 DEFERRED ECP Pyrexia Temperature 38 or above. Hypotension Systolic 90 0r below Haematocrit below 28% Recent MI Recent pulmonary Embolism or:- Deep Vein Thrombosis. Vomiting & Diarrhoea.
25 EVERY VISIT Medical history & clinical examination Drug history Blood tests (FBC,U&E,LFT,LDH,IGS, Bloods for research programme if patient consents ) Skin assessment (skin score, pruritus score) Karnovsky s Scale(Self assessment measure of patients quality of life) Gastrointestinal assessment Mouth assessment (Ulcers Lichnoid changes) FIRST VISIT AND THEN 3 MONTHLY Schirmer s test (for dry eyes) Joint measurements Respiratory function test Photos of any skin involvement
26 TREATMENT SCHEDULE Photopheresis is performed on two consecutive days Every 2-4 weeks ( for 14 weeks ) depending on condition treated. GVHD every 2 weeks. CTCL every 3-4 weeks. Depending on patients response will determine frequency of further treatments
27 TREATMENT SCHEDULE REVIEW 3 MONTHS:- Complete or partial response treatment 4 weekly. Minimal /or no response despite reduction of steroids by 50% continue 2 weekly. If neither of above stop treatment 6 MONTHS:- Complete response taper and stop. If > 50% reduction of steroids but less then partial response continue 4weekly and reduce immunosuppressant as tolerated IF no further response or progression of disease stop
28 DEFINITION OF A RESPONSE Complete response- resolution of active GVHD manifestations without systemic immunosuppression Partial response- >50% improvement of organ involvement scores from base line investigations or >50%reduction in immunosuppression. Minimal response-<50% improvement of organ involvement and or 25-50% reduction of Immunosuppression Stable disease-no improvement of organ involvement and no reduction in immunosuppression. Progressive disease- worsening of organ involvement or new disease in previously unaffected organs or increase in immunosuppression
29 ADVANTGES OF BLOOD PRIME PROCEDURE Can treat patients with low body weight (under 40kg) Can treat patients with low Haemoglobins (below 10) Can treat patients with low Haematocrits (below 28%) Reduces risks of Vasovagal episodes
30 DOES ECP WORK?
31 PRE TREATMENT 11 MONTHS LATER
32 January 2011 December 2011
33 THANK YOU Dr Peter Taylor. Dr Arun Alfred. Tracy Maher. Cheryl Swift. Rachel Goodgrove. Janet Mayo. Julie Ball. Freda Hammerton. Robert Whittle. Helen Denney. Director of Rotherham Photopheresis Haematology Consultant Unit Sister. Unit Sister Unit Sister Health Care Assistant. Research Nurse. Data Collection Manager. Research Scientist. Research Assistant.
Frequently Asked Questions About Photopheresis
PATIENT & CAREGIVER EDUCATION Frequently Asked Questions About Photopheresis This information explains photopheresis, including how to prepare for the procedure and what to expect afterward. What is photopheresis?
More informationCorporate Medical Policy
Corporate Medical Policy Extracorporeal Photopheresis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: extracorporeal_photopheresis 9/2010 8/2017 8/2018 8/2017 Description of Procedure
More informationThe impact of processing less blood with the Therakos Cellex Photopheresis System for pediatric patients
The impact of processing less blood with the Therakos Cellex Photopheresis System for pediatric patients Joanna Wigfield, DO Pediatric Hematology/Oncology Fellow Phoenix Children s Hospital Phoenix Children
More informationBlood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
More informationPrinciples And Practice For PHOTOPHERESIS
Principles And Practice For PHOTOPHERESIS Presented by Regina Mack, RN., HP(ASCP) Baylor Scott&White Health System Dallas, Texas Apheresis Department Warnings and Disclosures Off-label and investigative
More informationKavita Raj Consultant Haematologist KHP
Kavita Raj Consultant Haematologist KHP 1950s Billingham and Brent injection of spleen cells from adult mice into newborn mice Thickening and loss elasticity of skin, red soles, exfoliation, diarrhoea
More informationDEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
More informationExtracorporeal Photophoresis
Ontario Health Technology Assessment Series 2006; Vol. 6, No. 6 Extracorporeal Photophoresis An Evidence-Based Analysis March 2006 Medical Advisory Secretariat Ministry of Health and Long-Term Care 1 Suggested
More informationClinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
Clinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation Reference: NHS England F01X08/01 1 Information Reader Box (IRB)
More informationAN ESSENTIAL GUIDE TO GRAFT VERSUS HOST DISEASE (GvHD)
LIFE AFTER TRANSPLANT: AN ESSENTIAL GUIDE TO GRAFT VERSUS HOST DISEASE (GvHD) #BMTsupport Essential Guide To GvHD 1 Produced with support from the Jack Petchey Foundation, in memory of John Petchey. At
More informationSpecialised Services Policy: CP91 Extracorporeal Photophoresis (ECP) for the Treatment of Chronic Graft versus Host Disease in Adults
Specialised Services Policy: Extracorporeal Photophoresis (ECP) for the Treatment of Chronic Graft versus Host Disease in Adults Document Author: Specialised Planner Executive Lead: Director of Planning
More informationLeukemia. There are different types of leukemia and several treatment options for each type.
Leukemia Introduction Leukemia is the name of a group of cancers of the blood cells. Hundreds of thousands of people worldwide are diagnosed with leukemia each year. There are different types of leukemia
More informationTherapeutic Apheresis Services Annual Review 2016/17
Therapeutic Apheresis Services Annual Review 2016/17 NHS Blood and Transplant (NHSBT) is a major provider of Therapeutic Apheresis Services (TAS) in the NHS. Services are provided across England. Collection
More informationOneMatch Stem Cell and Marrow Network. Training Guide
OneMatch Stem Cell and Marrow Network Training Guide What is OneMatch all about? OneMatch is a Canadian Program that matches and coordinates the collection of stem cells from potential donors to help save
More informationECP & cgvhd. Thursday 17 May 2012 BBTS - Apheresis Birmingham. The Rotherham NHS Foundation Trust
ECP & cgvhd Thursday 17 May 2012 BBTS - Apheresis Birmingham 2 Objectives Chronic graft vs host disease What is Photopheresis? Chronic Graft vs Host Disease and Photopheresis Economics When? Assessments
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationInformation. about cancer
1 Information about cancer This chapter may help you answer simple questions about what cancer is and how it is treated. There are more than 200 different types of cancer and a range of treatments. Being
More informationHigh dose melphalan conditioning for autologous transplant (inpatient) Palatine treatment centre
High dose melphalan conditioning for autologous transplant (inpatient) High dose melphalan conditioning for autologous transplant (inpatient) Palatine treatment centre This leaflet is offered as a guide
More informationExtracorporeal Photopheresis Description
Subject: Extracorporeal Photopheresis Page: 1 of 36 Last Review Status/Date: September 2015 Extracorporeal Photopheresis Description Extracorporeal photopheresis (ECP) is a leukapheresis-based immunomodulatory
More informationSusan L. Pinkard, RN Manager, Therapeutic Apheresis Hoxworth Blood Center University Of Cincinnati Academic Health Center Cincinnati, Ohio
Susan L. Pinkard, RN Manager, Therapeutic Apheresis Hoxworth Blood Center University Of Cincinnati Academic Health Center Cincinnati, Ohio The Good: What indications we using to initiate photopheresis
More informationInformation on Azathioprine for Inflammatory Bowel Disease
Information on Azathioprine for Inflammatory Bowel Disease What is Azathioprine? Azathioprine belongs to a group of medicines called immunosuppressant(s). What is Azathioprine used for? Azathioprine is
More informationPentostatin (Nipent )
Pentostatin (Nipent ) Pentostatin (Nipent ) This leaflet is offered as a guide to you and your family. Your treatment will be fully explained by your doctor or nurse, who will be happy to answer any questions.
More informationExtracorporeal Photopheresis after Solid-Organ Transplant and for Graftversus-Host Disease, Autoimmune Disease and Cutaneous T-Cell Lymphoma
MP 8.01.16 Extracorporeal Photopheresis after Solid-Organ Transplant and for Graftversus-Host Disease, Autoimmune Disease and Cutaneous T-Cell Lymphoma Medical Policy Section Therapy Issue 12/2013 Original
More informationExtracorporeal Photopheresis
Extracorporeal Photopheresis Policy Number: 8.01.36 Last Review: 9/2014 Origination: 2/2002 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for extracorporeal
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationRelated Policies None
Medical Policy BCBSA Ref. Policy: 8.01.36 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Therapy Related Policies None DISCLAIMER Our medical policies are designed for informational purposes
More informationExtracorporeal Photopheresis and Crohn s Disease. Jill Adamski MD, PhD Transfusion Medicine Department of Pathology
Extracorporeal Photopheresis and Crohn s Disease Jill Adamski MD, PhD Transfusion Medicine Department of Pathology Outline 1. Crohn s Disease (CD) 2. Extracoporeal Photopheresis (ECP) 3. Pilot studies
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More informationTwo further publications by Leukaemia Research are available should you require further information about the transplant procedure itself:
Two further publications by Leukaemia Research are available should you require further information about the transplant procedure itself: Seven Steps Bone Marrow and Stem Cell Transplantation To order
More informationChronic Lymphocytic Leukemia (CLL)
Page 1 of 10 PATIENT EDUCATION Chronic Lymphocytic Leukemia (CLL) Introduction Chronic lymphocytic leukemia (CLL) is a type of cancer of the lymphocytes (a kind of white blood cell). It is also referred
More informationSynthetic hypericin (SGX301; VIMRxyn) for cutaneous T cell lymphoma, unspecified
NIHR Innovation Observatory Evidence Briefing: May 2017 Synthetic hypericin (SGX301; VIMRxyn) for cutaneous T cell lymphoma, unspecified NIHRIO (HSRIC) ID: 10761 NICE ID: 8375 LAY SUMMARY Cutaneous T cell
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationABVD. by infusion over 30 minutes. You will have treatment on Day 1 and Day 15 (this is one cycle) for 2, 3 or 6 cycles.
ABVD ABVD This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may
More informationA Guide for Patients and Caregivers
DLBCL Starting KYMRIAH A Guide for Patients and Caregivers APPROVED USE WHAT IS KYMRIAH? KYMRIAH (tisagenlecleucel) is made from your own white blood cells and is a prescription cancer treatment used in
More informationPhotopheresis Technical Challenges. Lindsay Palomino, BSN RN HP May 6, 2016
Photopheresis Technical Challenges Lindsay Palomino, BSN RN HP May 6, 2016 No relevant disclosures SCCA Apheresis Unit! Therakos CellEx Photopheresis System For technical challenges and troubleshooting:
More informationOxford Transplant Centre. Live donor kidney transplantation what if we are not a match?
Oxford Transplant Centre Live donor kidney transplantation what if we are not a match? page 2 You will already have been provided with information about different types of kidney transplant and the tests
More informationEarly diagnosis saves lives #SpotLeukaemia
Early diagnosis saves lives #SpotLeukaemia Leukaemia... is a blood cancer affects people of all ages Leukaemia symptoms are hard to spot, as they are similar to the symptoms of common, unrelated conditions.
More informationDepartment of Clinical Haematology. Chemotherapy. Information for patients. Page 1 of 12
Department of Clinical Haematology Chemotherapy Information for patients Page 1 of 12 You may find this booklet helpful if you or someone close to you is going to have chemotherapy. It explains: what chemotherapy
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationWiskott-Aldrich Syndrome
chapter 7 Wiskott-Aldrich Syndrome Wiskott-Aldrich syndrome is a primary immunodeficiency disease involving both T- and B-lymphocytes. In addition, the blood cells that help control bleeding, called platelets
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationMyeloma Haematology and Transplant Unit MPT
MPT Myeloma Haematology and Transplant Unit MPT This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
More informationAllogeneic Stem Cell Transplantation for Cutaneous T-cell Lymphoma: Updated results from a single center
Allogeneic Stem Cell Transplantation for Cutaneous T-cell Lymphoma: Updated results from a single center Madeleine Duvic, MD Professor and Deputy Chairman Blanche Bender Professor in Cancer Research Departments
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationBone Marrow (Stem Cell) Transplant for Sickle Cell Disease
Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient
More informationTreatment FLAG. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Treatment FLAG An information guide Treatment FLAG This leaflet is offered as a guide to you and your family. The possible benefits of treatment
More informationMyeloma Haematology and Transplant Unit
BCD Myeloma Haematology and Transplant Unit BCD This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
More informationChemotherapy education leaflet
Chemotherapy education leaflet Chemotherapy with Cytotoxic Medicines This leaflet gives a general overview about chemotherapy. It does not give details about individual chemotherapy medicines or advise
More informationHaematology. R - CEPP Chemotherapy
Haematology R - CEPP Chemotherapy This information is about R-CEPP chemotherapy, which is a treatment for Lymphoma. Lymphoma is a cancer of the lymphatic system a network of glands in the body that helps
More informationOral Etoposide (Lymphoma)
Oral Etoposide (Lymphoma) Oral Etoposide (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk
More informationMACE. Etoposide via an infusion (drip) over 1 hour, once a day for 5 days
MACE MACE This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may
More informationChIVPP. ChIVPP. Day 1 to 14 Chlorambucil tablets Procarbazine capsules Prednisolone tablets
ChIVPP ChIVPP This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationEpirubicin. Epirubicin
Epirubicin Epirubicin This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for
More informationHaematology. C = Cyclophosphamide (pronounced sigh clo fos fa mide)
Haematology CEPP Chemotherapy This information is about CEPP chemotherapy, which is a treatment for Lymphoma. Lymphoma is a cancer of the lymphatic system - a network of glands in the body that helps to
More informationCLL: A Guide for Patients and Caregivers CHRONIC LYMPHOCYTIC LEUKEMIA
CLL: A Guide for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC LYMPHOCYTIC LEUKEMIA MYELOMA Introduction In the U.S. In 2006, about 91,000 people were living with CLL In 2007, more than 15,000 people
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationVenesection Nursing Guidelines
Venesection Nursing Guidelines Rationale Patients requiring venesection on the Day Treatment Unit (DTU) fall into 3 main categories; patients diagnosed with: Polycythemia Rubra Vera Haemachromatosis Transfusion
More informationVinblastine (Lymphoma)
Vinblastine (Lymphoma) Vinblastine (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
More informationAll medicines have risks and benefits. Your doctor has weighed the risks of you being given Mabthera SC against the benefits expected for you.
New Zealand Consumer Medicine Information MABTHERA SC Rituximab 1400 mg solution for subcutaneous injection for non-hodgkin s Lymphoma and 1600mg solution for subcutaneous injection for chronic lymphocytic
More informationName of Policy: Extracorporeal Photopheresis
Name of Policy: Extracorporeal Photopheresis Policy #: 028 Latest Review Date: June 2014 Category: Therapy Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationMedication information for patients and families
Medication information for patients and families What is Imuran? Imuran is a medication that reduces the activity of the immune system. This type of medication is called an immunosuppressive. Imuran comes
More informationCarol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT
Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationIbrutinib (Imbruvica )
Ibrutinib (Imbruvica) Ibrutinib (Imbruvica ) This leaflet is offered as a guide to you and your family. Ibrutinib is a type of anti-cancer treatment called a targeted therapy. The aim of this treatment
More informationMyeloma Haematology and Transplant Unit CTD1
CTD1 Myeloma Haematology and Transplant Unit CTD1 This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of
More informationPatient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension
Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This
More informationMelanoma. Exceptional healthcare, personally delivered
Melanoma Exceptional healthcare, personally delivered What is Melanoma? Malignant Melanoma is a form of Skin Cancer which can start in a preexisting mole or normal looking skin. What causes Melanoma? Although
More informationIntraperitoneal Chemotherapy
Intraperitoneal Chemotherapy What is Intraperitoneal (IP) Chemotherapy? Intraperitoneal (IP) chemotherapy is a way to put some of your chemotherapy into your abdomen (also called the peritoneal cavity)
More informationHealth Bites Breast Cancer. Breast Cancer. Normal breast
Health Bites Breast Cancer Breast Cancer Normal breast The normal breast tissue varies in size and shape. The breasts rest in front of the rib cage. The breasts are made up of fatty tissue, milk ducts
More informationCVD: Cisplatin, Vinblastine, and Dacarbazine
PATIENT EDUCATION patienteducation.osumc.edu CVD: Cisplatin, Vinblastine, and Dacarbazine What is CVD? It is the short name for the drugs used in this chemotherapy treatment. The three drugs you will receive
More informationPackage leaflet: Information for the patient. KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab
Package leaflet: Information for the patient KEYTRUDA 25 mg/ml concentrate for solution for infusion pembrolizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationRetroperineal Lymph Node Dissection (RPLND)
Acute Services Division Information for patients about Retroperineal Lymph Node Dissection (RPLND) Introduction This booklet gives you information about surgery to remove the residual lymph nodes at the
More informationRadiation Therapy. This reference summary reviews what to expect during and after radiation therapy.
Radiation Therapy Introduction Radiation therapy is a very common treatment for a variety of cancers. Radiation therapy, also called radiotherapy, is a cancer treatment that uses high doses of radiation
More informationElements for a Public Summary
Safety concern CSF antibodies Routine risk minimisation measures Additional risk minimisation measures VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Reduction in the duration
More informationLymphomas: Current Therapy Approaches
Lymphomas: Current Therapy Approaches Carol S. Portlock, MD Memorial Sloan-Kettering Cancer Center Questions to Answer Prior to Treatment Is the diagnosis conclusive? What is the lymphoma stage/prognostic
More informationMalignant Melanoma Early Stage. A guide for patients
This melanoma patient brochure is designed to help educate melanoma patients and their caregivers. It was developed under the guidance of Dr. Michael Smylie, Professor, Department of Oncology, University
More informationPancreas transplants. What you need to know. Information for patients Sheffield Kidney Institute (Renal Unit)
Pancreas transplants What you need to know Information for patients Sheffield Kidney Institute (Renal Unit) page 2 of 16 What is the pancreas and why is it transplanted? The pancreas is part of the digestive
More informationNursing Care of the Dialysis Patient. Adrian Hordon, MSN, RN
Nursing Care of the Dialysis Patient Adrian Hordon, MSN, RN Understand principles of hemodialysis Recognize different access ports Identify side effects and complications Discuss nursing care for pre and
More informationHigh dose cytarabine (Lymphoma)
High dose cytarabine High dose cytarabine (Lymphoma) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk
More informationABVD. by infusion over 30 minutes. You will have treatment on Day 1 and Day 15 of a 28 day cycle. You will have 2, 3 or 6 cycles.
ABVD ABVD This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may
More informationFor practical information about using Revlimid, patients should read the package leaflet or contact their doctor or pharmacist.
EMA/113870/2017 EMEA/H/C/000717 EPAR summary for the public lenalidomide This is a summary of the European public assessment report (EPAR) for. It explains how the Agency assessed the medicine to recommend
More informationAlemtuzumab in Cutaneous Lymphoma
Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) 1. Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant 2. Palliative
More informationHave you ever managed patients who have experienced an adverse reaction to transfusion?
Have you ever managed patients who have experienced an adverse reaction to transfusion? A. Yes, often B. Yes, occasionally C. No A. 1 in 30 units? B. 1 in 100? C. 1 in 1000? D. 1 in 10,000? SHOT collects
More informationMitomycin C and Fluorouracil
Mitomycin C and Fluorouracil Mitomycin C and Fluorouracil This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the
More informationMedication Guide ACAM2000 Smallpox (Vaccinia) Vaccine, Live
Medication Guide ACAM2000 Smallpox (Vaccinia) Vaccine, Live Please read this Medication Guide before you receive a vaccination with ACAM2000. This Guide does not take the place of talking to your healthcare
More informationAfter a kidney transplant
The nursing staff will make sure that you are comfortable and will monitor the transplanted kidney to make sure it is working well. When you wake up you will notice that you will have a number of different
More informationFor the Patient: UMYLDREL
For the Patient: UMYLDREL Other Names: Treatment of Multiple Myeloma Using Lenalidomide (REVLIMID ) and Dexamethasone MY = MYeloma (tumour group) L = Lenalidomide D = Dexamethasone REL = RELapse Uses:
More informationMycophenolate Mofetil (MMF)
SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in
More informationVI.2 Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Leukaemia is a cancer that starts in the blood-forming cells of the bone marrow. Chronic lymphocytic leukaemia (CLL) is a type
More informationresearch paper Summary
research paper The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK
More informationCMC Annual Review of BLOODBORNE DISEASES. Prevention of Transmission for School Staff
CMC Annual Review of BLOODBORNE DISEASES Prevention of Transmission for School Staff Standard on Bloodborne Pathogens OSHA sets the standard of care We must have standards to follow in schools for everyone
More informationAcute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
More informationChapter 18. Chapter 18. BMT Survivor. As a patient, it is critical to keep building on your knowledge.
Chapter 18 As a patient, it is critical to keep building on your knowledge. BMT Survivor Chapter 18 Glossary of Terms Notes Activities to Keep Your Mind Sharp Chapter 18 Glossary of Terms Acute A sudden
More informationSodium Aurothiomalate (Myochrysine - Gold Compounds)
Sodium Aurothiomalate (Myochrysine - Gold Compounds) How does it work? Gold is a disease modifying anti-rheumatic drug (DMARD). DMARDS prevent damage to the joints and are used to treat inflammatory types
More informationPeripheral Blood Stem Cell Collection for Lymphoma Patients
Department of Clinical Haematology Peripheral Blood Stem Cell Collection for Lymphoma Patients Information for patients PI.37 March 2016 V.4.0 PBSC for Lymphoma patients You may find this booklet helpful
More information